PROGRAM SNAPSHOT

CRISPR Therapeutics — CTX213

🚀 Pack Leader Preclinical (IND-enabling)

The successor to a discontinued predecessor program — still preclinical, no human trial has started.

What's actually shown: CRISPR's newer, wholly-owned, “unencapsulated” immune-evasive program per its own current pipeline page — successor to and informed by the clinical learnings of CTX211, which is discontinued/superseded and no longer scored. No clinical trial has started for CTX213.

Last verified: 2026-08-24. Sources: CRISPR pipeline page, CRISPR 2026 strategic priorities update.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard